EGFR and neoplasm: Beyond cell-autonomous resistance, CAFs, as key components of the tumor microenvironment (TME), have been discovered to mediate resistance to anti-EGFR therapy in a context-dependent manner through increasing EGF and IGF-binding protein secretion [22,23].